AN umbrella review determines glucosamine provides slight pain reduction and doubtful structural protection in knee osteoarthritis. Synthesizing data across 19 systematic reviews and meta-analyses, investigators evaluated how oral formulations influence adult patient symptoms, joint mobility, and radiographic cartilage preservation. The rigorous evaluation employed robust variance estimation to resolve pervasive trial overlap and assess real-world clinical relevance across diverse healthcare settings.
Pooled analyses revealed a statistically significant reduction in knee pain on the visual analog scale, yielding a standardized mean difference of -0.36. However, this improvement sits at or just below the accepted minimal clinically important difference threshold of 0.37, equivalent to roughly 9 millimeters on a 100-millimeter scale. When assessed via the Western Ontario and McMaster Universities Osteoarthritis Index, pain reductions and functional improvements failed to reach statistical significance. The apparent divergence highlights the assay sensitivity of unidimensional pain scales compared to composite functional indices, which often dilute subtle analgesic changes in clinical trials.
Regarding disease progression, glucosamine demonstrated a statistically significant slowing of joint space narrowing with a pooled effect size of -0.32. Closer inspection reveals that this structural benefit was driven predominantly by long-duration trials using prescription crystalline glucosamine sulfate rather than over-the-counter hydrochloride preparations. Because structural disease modification requires multiyear adherence to detect minimal radiographic preservation, short-term supplementation offers negligible protection. Furthermore, clinical discordance between radiographic joint preservation and symptomatic pain relief remains a well-documented hallmark of knee osteoarthritis pathology.
Across all evaluated systematic reviews, adverse event rates for glucosamine remained comparable to placebo, confirming an exceptionally favorable safety profile. Serious safety concerns, gastrointestinal complications, or metabolic disturbances did not emerge across the pooled trial cohorts. Because most patients purchase these supplements out of pocket at substantial personal expense, clinicians should transparently contextualize these modest benefits against recurring financial costs during shared decision-making. Ultimately, glucosamine offers a benign adjunct for pain management, yet high-quality evidence supporting true disease-modifying utility remains limited.
Reference
Li Y et al. Glucosamine for knee osteoarthritis: an umbrella review. Front Nutr. 2026;13:1806413.
sss615 on Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
